Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Laird Bloom(Pfizer (United States)), Edward R. LaVallie(Boston University), Liqin Liu(MacroGenics (United States)), Ezio Bonvini(MacroGenics (United States)), Lisa Racie(Pfizer (United States)), Weijun Ma(Pfizer (United States)), Macy Jin(Pfizer (United States)), Paul A. Moore(Zymeworks (Canada)), W.S. Somers, Syd Johnson(MacroGenics (United States)), Amy King(Pfizer (United States)), Chad May(Pfizer (United States)), Khetemenee Lam(Pfizer (United States)), Bilian Li(Pfizer (United States)), Lily Zhu(Pfizer (United States)), Peter LaPan(Pfizer (United States)), Lidia Mosyak(Pfizer (United States)), Susan Benard(Pfizer (United States)), Lioudmila Tchistiakova(Pfizer (United States)), Hans‐Peter Gerber(Pearl River Community College), Dianah Barrett(Pfizer (United States)), Laura Lin(Pfizer (United States)), Scott Gatto(Pfizer (United States)), Gurunadh R. Chichili(Oklahoma Medical Research Foundation), Wayne R. Stochaj(Pfizer (United States)), Kelvin M. Kerns(Pfizer (United States)), Caryl Meade(Pfizer (United States)), Jocelyn Sanford(Pfizer (United States)), Aaron M. D’Antona(Pfizer (United States)), James R. Apgar(Pfizer (United States)), Kristine Svenson, Alfredo Darmanin Sheehan(Pfizer (Ireland)), Hua Li(Jiading District Central Hospital), Tao He(Heidelberg University), Emma Cummins(Pfizer (Ireland)), Steve Burke(MacroGenics (United States)), Cliona O’Sullivan(Pfizer (Ireland)), Matthew Lambert(Pfizer (Ireland)), Wei Cao(Central South University), Maya Arai, Ralph Alderson(MacroGenics (United States)), William J.J. Finlay(Pfizer (Ireland)), William E. Brady(Pfizer (United States)), Stéphane Olland, Yinhua Yang(MacroGenics (United States))
Cited by 94
Related Papers
A Shape-Based 3-D Scaffold Hopping Method and Its Application to a Bacterial Protein−Protein Interaction
|Journal of Medicinal Chemistry|2005|605
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
|British Journal of Cancer|2008|289